CAS: 461432-26-8; (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-Ethoxybenzyl)Phenyl)-6-(Hydroxymethyl)Tetrahydro-2H-Pyran-3,4,5-Triol

• 英文名称(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-Ethoxybenzyl)Phenyl)-6-(Hydroxymethyl)Tetrahydro-2H-Pyran-3,4,5-Triol
• 中文名称达格列嗪
• IUPAC名称(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
• 其它别名Dapagliflozin
• CAS编号461432-26-8
• MFCD编号:MFCD13182359
• EINECS号:639-683-0
• FDA UNII编号:1ULL0QJ8UC
• 分子式:C21H25ClO6
• 分子量:408.88
• 产品CID: 1461254
• 同类组份化合物CAS960404-48-2 (propanediol monohydrate)461432-26-8 (free base)
• 产品分类原料药

• 相似结构搜索
• InChIKey: JVHXJTBJCFBINQ-ADAARDCZSA-N
• InChI=1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t…
• 计算化学: 氢键受体数6.0氢键供体数4.0可旋转键数6.0

物理性质

• 熔点55-58°C
• 沸点609.0±55.0 °C(预测)
• 闪点322.139 °C
• 密度1.349
• pKa:13.23±0.70(预测)
• PSA:99.38
• LogP:1.8444
• 折射率1.614
• 蒸汽压0 mmHg at 25 °C
• 溶解性DMSO (Slightly), Methanol (Slightly)
• 外观形态白色至淡黄色固体
• 储存条件2-8°C
• 产品应用该化合物是一种强力和高度选择性的SGLT2抑制剂,在体外和动物模型中都表现出生物活性;在体内,它以报告的EC50为1.1 NM 有效抑制了人类SGL2, 显示SGL特2的选择性程度超过1 200倍,而SGLTT1 则显示,它实际上增加了尿液甘蔗排泄物.在血清2型糖尿病大鼠的血清素诱发型中,治疗显著降低了节食性血清糖和HBA1C的剂量.同样,在糖尿病DB/DB小鼠中,一周的DAPAGLEFLOS治疗显著提高了尿液糖排出量和血液甘蔗水平. 单剂量1毫克/千克口服剂量表明,它会增加小鼠24小时的尿质甘蔗产出,证实了它减少肾糖再吸附剂的主要功能.

MSDS等安全信息

• GHS象形图
• GHS符号GHS07 & GHS08 & GHS09;
  注释: Exclamation mark & Health hazard & Environment
• 危险类别急性毒性 类别4(经口)
  特定目标器官毒性-重复接触 类别1
  严重眼刺激 类别2
  水生慢性毒性 类别2
  特定目标器官毒性-重复接触 类别2
  水生慢性毒性 类别4
  严重眼损伤 类别1
  特定目标器官毒性 - 单次接触 类别3
  皮肤腐蚀/刺激 类别2
• 警示词Danger(危险)
• 危险描述H302 |吞咽有害.
  H372 |长期或反复接触损害器官.
  H319 |造成严重眼刺激.
  H411 |对水生生物有毒并具有长期持续影响.
  H373 |长期或反复接触可能损害器官.
  H413 |可能对水生生物造成长期有害影响.
  H318 |造成严重眼损伤.
  H335 |可能引起呼吸道刺激.
  H336 |可能引起嗜睡或头晕.
  H315 |造成皮肤刺激.
• 防范说明P264-P270-P301+P312-P330-P501-P260-P264-P270-P314-P501-P280-P305+P351+P338-P310

欧盟法规

上下游产品

合成工艺路线路线简述

• 合成目标产物 Dapagliflozin 主要起始原料 Dapagliflozin Tetraacetate
• 2088749-74-8 + 4254-15-3 = 461432-26-8 + 960404-48-2 + 4254-15-3
  反应条件:1.1 Reagents: Triethylsilane Catalysts: Boron Trifluoride Etherate Solvents: Acetonitrile; 0 - 25 °C; 6 - 8 H,15 - 25 °C1.2 Reagents: Water Solvents: Tert-Butyl Methyl Ether
  标题:Preparation Of Sglt-2 Inhibitors And Its Intermediates
  参考文献:China]
  
  461432-26-8 + 57-55-6 = 461432-26-8 + 960404-48-2 + 4254-15-3
  反应条件:1.1 Solvents: Isopropyl Acetate,Water; 20 Min,25 - 30 °C1.2 Solvents: Cyclohexane; 25 - 30 °C; 2 H,25 - 30 °C; 30 °C -> 20 °C; 6 H,15 - 20 °C1.3 Solvents: Isopropyl Acetate; 30 °C -> 50 °C; 30 Min,25 - 30 °C; 50 °C -> 30 °C; 15 Min,25 - 30 °C1.4 Solvents: Cyclohexane; 2 H,25 - 30 °C; 30 °C -> 20 °C; 2 H,15 - 20 °C
  标题:Process For The Preparation Of (1S)-1,5-Anhydro-1-C-[4-Chloro-3-[(4-Ethoxyphenyl)Methyl]Phenyl]-D-Glucitol (Dapagliflozin) And Its Solvate Thereof
  参考文献:World Intellectual Property Organization]
  
  = 461432-26-8 + 960404-48-2 + 4254-15-3 [标题:Reaction Conditions
  标题:Premix Of Dapagliflozin And Process For The Preparation Thereof
  参考文献:India]
  
  = 461432-26-8 + 960404-48-2 + 4254-15-3 [标题:Reaction Conditions
  标题:Bilayer Tablet Formulations
  参考文献:United States]
  
  = 461432-26-8 + 960404-48-2 + 4254-15-3 [标题:Reaction Conditions
  标题:Process For The Preparation Of (1S)-1,5-Anhydro-1-C-[4-Chloro-3-[(4-Ethoxyphenyl)Methyl]Phenyl]-D-Glucitol (Dapagliflozin) And Its Solvate Thereof
  参考文献:India]
  
  = 461432-26-8 + 960404-48-2 + 4254-15-3 [标题:Reaction Conditions
  标题:Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate
  参考文献:World Intellectual Property Organization]
  
  461432-25-7 + 4254-15-3 = 461432-26-8 + 960404-48-2 + 4254-15-3
  反应条件:1.1 Reagents: Sodium Hydroxide Solvents: Methanol,Water; 1.5 H,Rt -> 68 °C; 1 H,68 °C -> 65 °C; 0.5 H1.2 Solvents: Isopropyl Acetate; 25 °C; 10 Min1.3 1 H
  标题:Crystalline Solvates Of Amino Acid Complexes With (1S)-1,5-Anhydro-L-C-(3-((Phenyl)Methyl)Phenyl)-D-Glucitol Were Prepared As Sglt2 Inhibitors For The Treatment Of Diabetes
  参考文献:World Intellectual Property Organization]
  
  2001088-28-2 + 4254-15-3 = 461432-26-8 + 960404-48-2 + 4254-15-3
  反应条件:1.1 Reagents: Boron Trifluoride Etherate,Sodium Iodide Solvents: Acetonitrile; 25 - 30 °C; 3 H,30 - 35 °C1.2 Reagents: Triethylamine; 4 H,25 - 30 °C1.3 Reagents: Hydrochloric Acid Solvents: Water; Ph 2 - 31.4 Solvents: Cyclohexane,Water
  标题:Process For The Preparation Of Dapagliflozin
  参考文献:World Intellectual Property Organization]
  
  461432-26-8 = 461432-26-8 + 960404-48-2 + 4254-15-3
  反应条件:1.1 Solvents: Water; 35 °C -> 55 °C; 30 - 40 Min,50 - 55 °C1.2 Solvents: Cyclohexane
  标题:An Improved Process For Preparation Of Dapagliflozin Propanediol Monohydrate
  参考文献:World Intellectual Property Organization]
  
  = 461432-26-8 + 960404-48-2 + 4254-15-3 [标题:Reaction Conditions
  标题:Improved Process For Dapagliflozin Propanediol Monohydrate
  参考文献:India]
  
  = 461432-26-8 + 960404-48-2 + 4254-15-3 [标题:Reaction Conditions
  标题:An Improved Process For Preparation Of Dapagliflozin Propanediol Monohydrate
  参考文献:India]
  
  = 461432-26-8 + 960404-48-2 + 4254-15-3 [标题:Reaction Conditions
  标题:Process For The Preparation Of Dapagliflozin
  参考文献:India]
  
  = 461432-26-8 + 960404-48-2 + 4254-15-3 [标题:Reaction Conditions
  标题:Dapagliflozin Hemihydrate And Crystal Form Thereof,Preparation Method,And Pharmaceutical Composition Thereof
  参考文献:China]
  
  = 461432-26-8 + 960404-48-2 + 4254-15-3 [标题:Reaction Conditions
  标题:Drug Formulations Using Water Soluble Antioxidants
  参考文献:United States]
  
  = 461432-26-8 + 960404-48-2 + 4254-15-3 [标题:Reaction Conditions
  标题:Bilayer Tablet Formulations Containing Metformin And Sglt2 Inhibitor
  参考文献:World Intellectual Property Organization

海关参考信息

• 2902600000-乙苯
  2903919090-氯苯
  2905122000-异丙醇
  2905310000-1,2-乙二醇
• 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
• 详情请参考：📖 海关编码查询和海关进出口税则

专利信息

其他信息查阅

• ➥ 象形图和危险代码
• ➥ 防范代码详解
• ➥ 危险代码说明
• ➥ Globally Harmonized System
• ➥ REACH监管